Clinical Trials Logo

Metastasis clinical trials

View clinical trials related to Metastasis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01169116 Withdrawn - Cancer Clinical Trials

Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis

Start date: July 2010
Phase: Phase 2
Study type: Interventional

Patients with single brain metastasis without other metastatic site have a better prognosis, and they need a better brain metastasis control. For non-resectable and non-radiosurgical brain metastasis, the gold standard treatment is whole-brain irradiation with 30 Gy in 10 fractions, but the local control is not achieved in most of the cases. This study investigate the possibility to increase radiation dose in this metastasis with exclusive hypofractionated stereotactic radiotherapy.

NCT ID: NCT01157039 Withdrawn - Colorectal Cancer Clinical Trials

A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The investigators hypothesize that glutamine significantly reduces the incidence and severity of peripheral neuropathy in patients receiving oxaliplatin for metastatic colorectal cancer, decreases the need for dose reduction of oxaliplatin, and it does not impair oxaliplatin efficacy or pharmacokinetics.

NCT ID: NCT00244348 Withdrawn - Colorectal Cancer Clinical Trials

Hepatic Artery Infusion With Oxaliplatin

Start date: October 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Hepatic artery infusion (HAI) with oxaliplatin (OX), systemic 5 fluorouracil (5FU), and leucovorin (HAI/OX/FU) will be implemented using an interventional radiology technique to obviate the need for initial major surgery (catheter placement) in patients who have unresectable liver metastasis from colorectal cancer. The study goal is to reduce tumor size to make possible a complete resection of all lesions. Secondary goals are to reduce or eliminate the complexity usually associated with HAI, to accomplish most or all of the treatment as an outpatient, to reduce costs, and to avoid the hepatotoxicity associated with HAI/floxuridine (FUDR). Oxaliplatin has been selected because of its ease of use, known toxicology, and established efficacy in colorectal cancer.